Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.

@article{Garton2017AntiKITMA,
  title={Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.},
  author={Andrew J. Garton and Scott B Seibel and Lori Lopresti-Morrow and Linda Crew and Neal Janson and Sreekala Mandiyan and Eduardo S Trombetta and Shannon Pankratz and Theresa M Lavallee and Richard Gedrich},
  journal={Molecular cancer therapeutics},
  year={2017},
  volume={16 4},
  pages={
          671-680
        }
}
The receptor tyrosine kinase KIT is an established oncogenic driver of tumor growth in certain tumor types, including gastrointestinal stromal tumors, in which constitutively active mutant forms of KIT represent an actionable target for small-molecule tyrosine kinase inhibitors. There is also considerable potential for KIT to influence tumor growth indirectly based on its expression and function in cell types of the innate immune system, most notably mast cells. We have evaluated syngeneic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS